These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6348806)

  • 1. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of prostacyclin: formation of an active metabolite in the liver.
    Wong PY; Lee WH; Quilley CP; McGiff JC
    Fed Proc; 1981 May; 40(7):2001-4. PubMed ID: 7014260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
    J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic inactivation of 6-keto-prostaglandin E1 in vitro: comparison with prostaglandin E1.
    Berry CN; Hoult JR; Griffiths RJ; Moore PK
    Biochem Pharmacol; 1984 Apr; 33(8):1277-84. PubMed ID: 6549614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of 6-keto prostaglandin E1 in mammalian kidneys.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 May; 79(1):149-55. PubMed ID: 6347300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.
    Quilley CP; McGiff JC; Lee WH; Sun FF; Wong PY
    Hypertension; 1980; 2(4):524-8. PubMed ID: 6995292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells.
    Oliva D; Bernini F; Corsini A; Nicosia S
    Biochem Pharmacol; 1984 Dec; 33(23):3755-8. PubMed ID: 6391491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
    Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
    Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catabolism of 6 keto PGE1: biological activation by the rat kidney in vitro.
    Moore PK; Griffiths RJ; Gaffen ZA
    Eur J Pharmacol; 1983 Jul; 91(2-3):311-5. PubMed ID: 6684573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
    Neuman SD; Raisz LG
    Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit.
    Pieroni JP; Dray F; Pace-Asciak CR; McGiff JC
    J Pharmacol Exp Ther; 1988 Oct; 247(1):63-8. PubMed ID: 3139870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascorbic acid enhances the formation of prostaglandin E1 in washed human platelets and prostacyclin in rat aortic rings.
    Srivastava KC
    Prostaglandins Leukot Med; 1985 May; 18(2):227-33. PubMed ID: 3925463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activities of 6-keto-prostaglandin E1.
    Lewis R; Schölkens BA; Beck G
    Prostaglandins Leukot Med; 1984 Dec; 16(3):303-24. PubMed ID: 6098901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
    Hyman AL; Kadowitz PJ
    J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.